Scarica l'app Stockscreener
37.73
0.68%
-0.26
Dopo l'orario di chiusura:
37.40
-0.33
-0.87%
Precedente Chiudi:
$37.99
Aprire:
$37.65
Volume 24 ore:
1.40M
Relative Volume:
0.50
Capitalizzazione di mercato:
$5.07B
Reddito:
-
Utile/perdita netta:
$-237.54M
Rapporto P/E:
-15.07
EPS:
-2.5033
Flusso di cassa netto:
$-145.05M
1 W Prestazione:
-0.71%
1M Prestazione:
-16.43%
6M Prestazione:
+98.06%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$37.17
$38.19
Intervallo di 1 settimana:
$37.17
$39.26
Portata 52W:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Nome
Definium Therapeutics Inc
Settore
Industria
Telefono
212-220-6633
Indirizzo
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
37.73 | 5.10B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | Stifel | Buy |
| 2026-04-10 | Iniziato | Piper Sandler | Overweight |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-30 | Iniziato | Jefferies | Buy |
| 2025-10-13 | Iniziato | Needham | Buy |
| 2025-08-04 | Ripresa | Oppenheimer | Outperform |
| 2025-01-28 | Iniziato | Evercore ISI | Outperform |
| 2024-12-20 | Iniziato | Chardan Capital Markets | Buy |
| 2024-10-14 | Ripresa | Leerink Partners | Outperform |
| 2024-07-24 | Iniziato | ROTH MKM | Buy |
| 2024-05-29 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-15 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | Canaccord Genuity | Buy |
| 2022-12-09 | Ripresa | ROTH Capital | Buy |
| 2022-11-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-08-26 | Iniziato | Oppenheimer | Outperform |
| 2022-08-10 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Iniziato | ROTH Capital | Buy |
| 2021-06-28 | Iniziato | Maxim Group | Buy |
Mostra tutto
Definium Therapeutics Inc Borsa (DFTX) Ultime notizie
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress - Moomoo
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics (DFTX) CEO gets 40K-share award, sells stock for taxes - Stock Titan
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - Kalkine
Transcript : Definium Therapeutics, Inc.Special Call - marketscreener.com
After $1.23M sale, Definium Therapeutics (DFTX) holder plans another stock trade - Stock Titan
Stifel reiterates Buy on Definium Therapeutics stock, $60 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on Definium Therapeutics stock, $60 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Definium Therapeutics Announces New Employee Inducement Grants - The Chronicle-Journal
Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72 - moomoo.com
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Stifel confident in Definium Therapeutics stock after management dinner By Investing.com - Investing.com Nigeria
Stifel confident in Definium Therapeutics stock after management dinner - Investing.com
SW Weekly: Why I Can't Buy Definium Following Phase 3 LSD Readout. (NASDAQ:DFTX) - Seeking Alpha
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Business Wire
Certain Common Shares of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
Certain Warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - TradingView
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
Definium Therapeutics Inc Azioni (DFTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):